Medidata Solutions Introduces Rave Safety Gateway
NEW YORK, N.Y. – December 3, 2009
Medidata Solutions, a global provider of hosted clinical development solutions, announced the introduction of Rave Safety Gateway, the newest extension to its Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) solution. Rave Safety Gateway provides clinical research sponsors and contract research organizations (CROs) with a more efficient and accurate solution to perform the time-critical task of collecting and transmitting serious adverse events (SAEs) and related data from sites to safety reporting systems.
Global regulatory agencies enforce stringent guidelines for timely reporting of SAEs by sites and sponsors during clinical trials. Today's process of collecting complete and accurate SAE information relies heavily on multiple exchanges between sites and sponsors. Safety teams must manually enter all SAE information into a safety reporting system, even though much of this data has already been captured by sites in an EDC system. In addition, sites must bear the burden of communicating this information to sponsors via a separate paper process. These laborious and redundant manual efforts are further compounded by the need to reconcile clinical and safety data at the end of a trial.
Medidata Rave Safety Gateway addresses these inefficiencies by providing built-in functionality that automatically transmits safety case data entered at sites to sponsors' safety reporting systems using the International Conference on Harmonization (ICH) industry standard E2B file format. By doing so, both sites and sponsors can leverage efforts already put forward in entering safety related data into the EDC system, thus significantly reducing the burden of collecting and reconciling safety data.
“The introduction of Rave Safety Gateway offers our clients the opportunity to achieve significant efficiency improvements by streamlining their safety data collection and transmission processes,” said Glen de Vries, president of Medidata Solutions.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
